/ALVAL.PA
ALVAL.PA Stock - Valbiotis S.A.
Healthcare|BiotechnologyPAR
$0.69+4.72%
+$0.03 (+4.72%) • Dec 23
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.19
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.76
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALVAL.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.68 – $0.69
TARGET (TP)$0.79
STOP LOSS$0.63
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.41
52W High$1.68
52W Low$0.54
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $175,000 | $4.73M | $785,000 | $298,000 | $3.09M |
| Gross Profit | $-2,443,000 | $2.69M | $767,000 | $282,000 | $3.09M |
| Gross Margin | -1396.0% | 56.8% | 97.7% | 94.6% | 99.9% |
| Operating Income | $-10,423,000 | $-7,160,000 | $-14,055,000 | $-10,871,000 | $-5,414,000 |
| Net Income | $-10,025,000 | $-7,368,000 | $-12,312,000 | $-8,681,000 | $-3,829,000 |
| Net Margin | -5728.6% | -155.7% | -1568.4% | -2913.1% | -123.8% |
| EPS | $-0.63 | $-0.59 | $-1.22 | $-0.95 | $-0.51 |
Company Overview
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ALVAL.PABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.41
Q1 2025
EPS Surprise History
Q3 21
No data
Q2 22
No data
Q3 22
No data
Q1 23
No data
Q3 23
No data
Q2 24
No data
Q4 24
No data
Q1 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 2, 2026 | — | — | — | — |
Q4 2025 | Oct 9, 2025 | — | — | — | — |
Q1 2025 | Mar 3, 2025 | — | $-0.41 | — | — |
Q4 2024 | Oct 30, 2024 | — | $-0.28 | — | — |
Q2 2024 | Apr 26, 2024 | — | $-0.44 | — | — |
Q3 2023 | Sep 29, 2023 | — | $-0.16 | — | — |
Q1 2023 | Mar 16, 2023 | — | $-0.69 | — | — |
Q3 2022 | Sep 15, 2022 | — | $-0.52 | — | — |
Q2 2022 | May 20, 2022 | — | $-0.54 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.40 | — | — |
Q1 2021 | Mar 17, 2021 | — | $-0.12 | — | — |
Q3 2020 | Jul 29, 2020 | — | $-0.41 | — | — |
Q2 2020 | Apr 21, 2020 | — | $-0.51 | — | — |
Q3 2019 | Aug 30, 2019 | — | $-0.66 | — | — |
Q1 2019 | Mar 8, 2019 | — | $-0.77 | — | — |
Q3 2018 | Sep 21, 2018 | — | $-0.54 | — | — |
Q2 2018 | Apr 3, 2018 | — | $-1.26 | — | — |
Q3 2017 | Sep 29, 2017 | — | $-0.10 | — | — |
Q2 2017 | May 16, 2017 | — | $-0.16 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.10 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ALVAL.PA
What is ALVAL.PA's current stock price?
Valbiotis S.A. (ALVAL.PA) is currently trading at $0.69 per share. The stock has moved +4.72% today.
What is the analyst price target for ALVAL.PA?
No analyst price targets are currently available for this stock.
What sector is Valbiotis S.A. in?
Valbiotis S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the PAR exchange.
What is ALVAL.PA's market cap?
Valbiotis S.A. has a market capitalization of $0.02 billion, making it a small-cap company.
Does ALVAL.PA pay dividends?
No, Valbiotis S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAELIS.PA
Aelis Farma S.A.
$1.07
Mkt Cap: $0.0B
ALBIO.PA
Biosynex S.A.
$0.58
Mkt Cap: $0.0B
ALCOX.PA
Nicox S.A.
$0.29
Mkt Cap: $0.0B
ALINS.PA
Intrasense S.A.
$0.25
Mkt Cap: $0.0B
ALNFL.PA
NFL Biosciences S.A.
$1.16
Mkt Cap: $0.0B
ALPAT.PA
Plant Advanced Technologies S.A.
$8.46
Mkt Cap: $0.0B
ALTHX.PA
THX Pharma
$2.02
Mkt Cap: $0.0B
ALTME.PA
TME Pharma N.V.
$0.06
Mkt Cap: $0.0B
POXEL.PA
Poxel S.A.
$0.24
Mkt Cap: $0.0B
SIGHT.PA
GenSight Biologics S.A.
$0.11
Mkt Cap: $0.0B
Explore stocks similar to ALVAL.PA for comparison